Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company specializing in the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platforms include PolyXen™, which enhances the half-life and other pharmacological properties of biologic drugs.
Xenetic’s lead investigational product candidates comprise the FDA orphan-designated oncology therapeutic Sodium Cridanimod for progesterone receptor-negative endometrial cancer, and a polysialylated form of erythropoietin for treating anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also collaborating with Shire PLC (formerly Baxalta, Baxter Incorporated, and Baxter Healthcare) to develop polysialylated blood coagulation factors, including a next-generation Factor VIII.
In the immune-oncology space, Xenetic is advancing XCART, a personalized CAR T platform technology, and the DNase platform aimed at improving existing treatments by targeting neutrophil extracellular traps (NETs) implicated in cancer progression and resistance. The company is working towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Recent financial updates reveal that Xenetic ended Q2 2023 with approximately $10.7 million in cash and no debt. The company reported a net loss of $1.1 million for Q3 2023 and continued to secure strategic collaborations and advance its DNase-based oncology program.
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company focusing on innovative immune-oncology technologies for hard-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Jim Parslow, the company's Interim CEO and CFO, delivered a presentation at the event. The video webcast of this presentation is now available on the Events page in the Investors section of Xenetic's website (www.XeneticBio.com) and will remain accessible for 90 days.
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2024 financial results and provided a business update. Key highlights include:
1. Ongoing preclinical studies with data expected before year-end
2. Focus on demonstrating DNase-based oncology program in clinical proof-of-concept studies
3. Q2 2024 net loss of $1.3 million
4. R&D expenses remained flat at $0.9 million
5. G&A expenses increased by 19.5% to $1.1 million
6. Royalty payments of $0.7 million, an 11.6% increase year-over-year
7. Cash position of $7.3 million at quarter-end
The company remains confident in its DNase-based oncology platform and is advancing towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.
Xenetic Biosciences has announced the appointment of James F. Parslow as the interim Chief Executive Officer, effective May 16, 2024. Parslow, currently the Chief Financial Officer, will lead the company as it focuses on advancing its immune-oncology technologies. The company aims to drive its pipeline toward a first human clinical study and extend its cash runway. Xenetic is moving forward with its DNase-based oncology program, targeting pancreatic carcinoma and other advanced solid tumors, with preclinical data expected by year-end.
Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2024, highlighting ongoing preclinical studies, advancement of DNase-based oncology program, and ending the quarter with $7.8 million in cash. The net loss for the quarter was approximately $1.2 million, with research & development expenses increasing by 58.6% and general and administrative expenses decreasing by 9.8% compared to the same quarter in 2023.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What is Xenetic Biosciences' main focus?
What are the primary platforms used by Xenetic Biosciences?
What are Xenetic Biosciences' lead investigational products?
Who are Xenetic Biosciences' key partners?
What is the focus of Xenetic's DNase platform?
What are the company's recent financial highlights?
What is the goal of Xenetic's XCART technology?
What are the company’s plans for its DNase-based oncology program?
How does the PolyXen™ platform benefit biologic drugs?
Where can I find more information about Xenetic Biosciences?
